78 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28650658	54	Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.	Shandong University
28375629	84	Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain.	Pfizer
28347667	35	Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.	Nanchang University
28280261	84	Non-kinase targets of protein kinase inhibitors.	The University Of Sydney
27994766	28	Discovery of New Bromodomain Scaffolds by Biosensor Fragment Screening.	University Of Dundee
27682507	167	Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.	Genentech
27673482	4	Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.	Ludwig-Maximilians-Universit£T M£Nchen
27266999	16	Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.	Zhejiang University
27774127	75	Discovery of a Series of 5,11-Dihydro-6	Dana-Farber Cancer Institute
26914985	124	Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.	Boehringer Ingelheim Rcv
27142751	22	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.	China Pharmaceutical University
27190605	77	Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).	Constellation Pharmaceuticals
26731611	30	4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1).	Albert-Ludwigs-University Of Freiburg
26572217	60	Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.	Genentech
26985285	4	Dihydropteridinone Inhibitors of BRD4.	Dart Neuroscience
26731490	99	Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.	Guangzhou Institutes Of Biomedicine And Health
26701186	50	KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.	University Of Freiburg
26061247	71	Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.	The University Of Texas M.D. Anderson Cancer Center
26869194	1	A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor.	Mitsubishi Tanabe Pharma
26735842	27	Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.	Centre National de la Recherche Scientifique/INSERM/ULP
26367539	22	New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.	University Of Dundee
26043365	41	Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.	University Of Z£Rich
25799074	65	Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.	Glaxosmithkline
26191363	29	BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.	University Of Maryland
25678016	15	Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.	The University Of Tokyo
26230603	176	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.	Glaxosmithkline
26022843	39	Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.	Amri
26155854	125	Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors.	Glaxosmithkline
26080064	141	Structure-Based Design of¿-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.	University Of Michigan
25559428	38	Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.	Shanghai Institute Of Materia Medica
25408830	43	1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.	Glaxosmithkline
25314271	44	Biased multicomponent reactions to develop novel bromodomain inhibitors.	Dana-Farber Institute
25249180	146	The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.	Glaxosmithkline
24767840	2	Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.	University Of Zurich
24144283	100	Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.	Icahn School Of Medicine At Mount Sinai
24090311	12	Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.	The Institute Of Cancer Research
24015967	71	Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.	Glaxosmithkline
24900758	44	Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.	Constellation Pharmaceuticals
23530754	25	Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain.	Chinese Academy Of Sciences
23517011	29	Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.	University Of Oxford
22726925	216	Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.	Cellzome
23095041	16	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.	Pfizer
22924434	4	Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.	University Of Oxford
22437115	66	Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).	Glaxosmithkline
22136469	148	Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.	Glaxosmithkline
21742492	1	Peptoid ligands that bind selectively to phosphoproteins.	The Scripps Research Institute
21568322	16	Discovery and characterization of small molecule inhibitors of the BET family bromodomains.	Glaxosmithkline
24900532	1	Bromodomains: are readers right for epigenetic therapy?	TBA
22316554	22	Development of live-cell imaging probes for monitoring histone modifications.	Japan Science And Technology Agency
22137933	6	Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.	University Of Oxford
22136404	9	Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.	Glaxosmithkline
21851057	30	3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.	University Of Oxford
28949521	88	Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.	Abbvie
28910100	2	Direct NMR Probing of Hydration Shells of Protein Ligand Interfaces and Its Application to Drug Design.	University Of Vienna
28535045	64	BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.	University Of Minnesota
19117760	19	Structure-based virtual screening for novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase and their experimental evaluation.	Northern Kentucky University
19781947	5	Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.	Universite De Lyon
16028929	17	Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.	Yale University
19097784	55	Discovery of thiophene inhibitors of polo-like kinase.	Gsk
19138846	23	Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.	Gsk
17004711	85	Antibacterial agent discovery using thymidylate synthase biolibrary screening.	Unimore
782880	21	Influence of side-chain structure of aliphatic amino acids on binding to isoleucyl-tRNA synthetase from Escherichia coli MRE 600.	Gesellschaft Fur Molekularbiolische Forschung Mbh
11341829	9	Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action.	Pharmacia
17154512	78	2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase i	Bristol-Myers Squibb
16386899	13	Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors.	Hawaii Biotech
15055992	77	Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives.	Biocryst Pharmaceuticals
15723556	4	Use of binding enthalpy to drive an allosteric transition.	University Of Maryland
12044152	4	DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose.	Umr Cnrs 6032